Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.38 | — | — | 1.32 | — | — | — | — | — | 37.00 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9.02 | 3.59 | 55.91 | 30.90 | 585.19 | 1082.38 | 65.81 | 24.94 | 21.50 | 22.78 | 60.03 | 79.76 | — |
| — | -99.7% | -15.0% | +23.9% | +2621.9% | +4650.9% | +9.6% | -68.7% | — | — | — | — | — | |
| P/B Ratio | 0.14 | 0.13 | 1.12 | 1.22 | 2.20 | 1.69 | 1.63 | 1.64 | 1.05 | 1.82 | 2.50 | 2.36 | — |
| — | -92.2% | -31.2% | -25.7% | +109.8% | -7.2% | -34.7% | -30.5% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 0.60 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
PureTech Health plc's operating margin was -1801.7% in Q4 2025, up 787.7 pp QoQ and up 37108.4 pp YoY. The trailing four-quarter average of -7294.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 104.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 41.0% | -1245.2% | 1066.7% | -13416.7% | -940.0% | 2.8% | -276.6% | -501.6% | -640.2% | -314.1% | -295.5% | -458.9% |
| — | +104.4% | -44172.3% | +485.6% | -2575.0% | -46.8% | +100.9% | +6.4% | -9.3% | +41.6% | +25.0% | -64.2% | +19.2% | |
| Operating Margin | -2114.7% | -1801.7% | -2589.5% | -1730.7% | -23054.9% | -38910.1% | -2417.8% | -1125.0% | -1439.4% | -711.6% | -1166.6% | -1355.6% | -771.2% |
| — | +95.4% | -7.1% | -53.8% | -1501.6% | -5368.1% | -107.3% | +17.0% | -86.6% | +40.7% | +27.2% | -313.7% | +26.7% | |
| Net Margin | -2355.4% | -2319.6% | -2409.8% | 2366.1% | -14504.5% | -22606.7% | -793.8% | -256.3% | -403.2% | 128.4% | -1291.9% | -2395.9% | 1811.2% |
| — | +89.7% | -203.6% | +1023.2% | -3497.5% | -17701.5% | +38.6% | +89.3% | -122.3% | -98.2% | -300.0% | -939.8% | +1332.3% |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.8% | -19.2% | -11.5% | 26.7% | -10.9% | -8.3% | -4.7% | -4.1% | -4.9% | 2.6% | -12.4% | -16.3% | 17.5% |
| — | -130.4% | -142.6% | +749.3% | -123.7% | -419.3% | +61.9% | +74.8% | -127.9% | -97.2% | -182.0% | +13.8% | +436.0% | |
| ROA | -19.3% | -11.9% | -7.7% | 16.1% | -6.6% | -5.8% | -3.6% | -3.0% | -3.2% | 1.6% | -8.0% | -11.1% | 12.1% |
| — | -105.0% | -115.5% | +632.5% | -104.7% | -458.0% | +55.2% | +72.6% | -126.5% | -96.8% | -249.5% | -33.4% | +741.4% | |
| ROIC | -66.9% | -37.9% | -25.9% | -59.9% | -31.4% | -21.9% | -18.2% | -21.6% | -35.4% | -33.7% | -19.4% | -12.4% | -7.7% |
| — | -73.5% | -42.5% | -176.7% | +11.4% | +35.0% | +6.5% | -74.1% | -357.3% | -137.4% | +62.7% | +67.7% | +86.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.06 | 0.05 | 0.09 | 0.06 | 0.05 | 0.09 | 0.08 | 0.09 | 0.14 | 0.12 | 0.05 |
| — | +16.9% | +13.7% | -36.0% | +6.7% | -37.9% | -63.6% | -27.0% | +66.5% | +47.4% | -55.6% | +58.3% | -12.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.59 | 6.59 | 8.49 | 9.33 | 3.68 | 6.76 | 7.31 | 3.99 | 2.54 | 2.22 | 2.11 | 2.29 | 2.22 |
| — | -2.5% | +16.1% | +134.1% | +44.8% | +204.6% | +246.7% | +74.1% | +14.3% | +82.9% | +204.9% | +134.3% | +128.9% | |
| Quick Ratio | 6.59 | 6.59 | 8.49 | 9.33 | 3.68 | 6.76 | 7.31 | 3.99 | 2.54 | 2.22 | 2.11 | 2.29 | 2.22 |
| — | -2.5% | +16.1% | +134.1% | +44.8% | +204.6% | +246.7% | +74.1% | +14.3% | +82.9% | +196.7% | +134.3% | +128.9% | |
| Interest Coverage | -1.42 | -1.13 | -50.24 | 74.84 | -5.84 | -1.54 | -7.63 | -23.13 | — | — | — | — | 2021.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRTC stock.
PureTech Health plc's current P/E is -0.4x. The average P/E over the last 1 quarters is 1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PureTech Health plc's current operating margin is -2114.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PureTech Health plc's business trajectory between earnings reports.